CD79A and irritable bowel syndrome: An Asian study revealed that 18% of IBS patients fulfilling the Rome III criteria were positive for anti-deamidated gliadin peptide IgA antibodies (IgA DGP), and 13% demonstrated a low-grade increase in intraepithelial lymphocytes in duodenal biopsies, and only one of them diagnosed with IBS 2 years ago met the criteria of celiac disease, indicating that a subset of IBS patients had an immunological response to gluten (Lu et al., 2014).